France preventive inhaler market is anticipated to grow at a substantial rate of 3.3% during the forecast period. As per French government agency, Business France, the country ranked as 4th globally and second in Europe for the medical device and technology industry. There are about 1,300 to 1,350 companies in French device manufacturer that generated a revenue of around $32 billion in 2017. The country is generating about $9.5 billion in 2017 by the export of medical devices. The medical device market is employing around 85,000 people in the country. This provides a significant base for the growth of a preventive inhaler market over the forecast period.

France preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of the device, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the France preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. 

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the France preventive inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Air Liquide S.A. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. 

A major inhaler manufacturing company in France is Air Liquide. In April 2018, the company acquired a French start-up company EOVE for the extension of service offering of home healthcare activities. In September 2017 Air Liquide acquired Sogo Sangyo Kabushiki Kaisha for expanding its healthcare business in Japan. In September 2017 company has launched its first e-health solution Chronic care Connect which is a remote monitoring solution. In January 2017 Air Liquide acquired Oxymaster for expanding its healthcare business in South America.

Research Methodology

The market study of the France preventive inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. France Preventive Inhaler Market Research and Analysis by Device Type

2. France Preventive Inhaler Market Research and Analysis by Application

3. France Preventive Inhaler Market Research and Analysis by End-User

The Report covers:

• Comprehensive research methodology of the France preventive inhaler market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the France preventive inhaler market.
• Insights about market determinants which are stimulating the France preventive inhaler market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.